Receptor Tyrosine Kinases (RTKs) are necessary for numerous cell-signaling events which promote cell growth and replication. RTK-1 activation leads to signaling through Ras/Rap/MAPK pathway.
A rare mutation resulting in a constitutively active form of RTK-1 causes a rare form of leukemia. Using a drug which binds close to an ATP binding pocket prevents tumor growth.
How might this drug alter RTK-1 activity?